BidaskClub lowered shares of Myriad Genetics (NASDAQ:MYGN) from a hold rating to a sell rating in a research report report published on Wednesday morning.

MYGN has been the topic of a number of other reports. Barclays increased their price target on shares of Myriad Genetics from $35.00 to $38.00 and gave the company an equal weight rating in a research report on Wednesday, August 22nd. Zacks Investment Research downgraded shares of Myriad Genetics from a buy rating to a hold rating in a research report on Monday, October 29th. Deutsche Bank increased their price target on shares of Myriad Genetics from $37.00 to $43.00 and gave the company a hold rating in a research report on Monday, November 5th. Piper Jaffray Companies upgraded shares of Myriad Genetics from a neutral rating to an overweight rating and increased their price target for the company from $38.00 to $53.00 in a research report on Wednesday, October 10th. Finally, TheStreet downgraded shares of Myriad Genetics from a b rating to a c rating in a research report on Thursday, November 8th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. Myriad Genetics has an average rating of Hold and an average price target of $41.90.

Shares of NASDAQ MYGN opened at $31.51 on Wednesday. The stock has a market capitalization of $2.40 billion, a PE ratio of 23.80, a price-to-earnings-growth ratio of 1.86 and a beta of 0.36. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.83 and a current ratio of 3.17. Myriad Genetics has a 1 year low of $27.27 and a 1 year high of $50.44.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, November 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.13. The company had revenue of $202.30 million for the quarter, compared to analyst estimates of $203.20 million. Myriad Genetics had a net margin of 7.07% and a return on equity of 10.07%. The company’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 EPS. Analysts expect that Myriad Genetics will post 1.5 EPS for the current year.

Hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC raised its holdings in Myriad Genetics by 2.6% during the 3rd quarter. Acadian Asset Management LLC now owns 2,387,166 shares of the company’s stock worth $109,812,000 after buying an additional 59,446 shares during the period. GHP Investment Advisors Inc. raised its holdings in Myriad Genetics by 4.5% during the 2nd quarter. GHP Investment Advisors Inc. now owns 53,290 shares of the company’s stock worth $1,991,000 after buying an additional 2,305 shares during the period. United Services Automobile Association raised its holdings in Myriad Genetics by 206.8% during the 2nd quarter. United Services Automobile Association now owns 104,981 shares of the company’s stock worth $1,916,000 after buying an additional 70,766 shares during the period. Swiss National Bank raised its holdings in Myriad Genetics by 2.6% during the 2nd quarter. Swiss National Bank now owns 121,600 shares of the company’s stock worth $4,544,000 after buying an additional 3,100 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in Myriad Genetics by 76.8% during the 2nd quarter. Wells Fargo & Company MN now owns 376,515 shares of the company’s stock worth $14,071,000 after buying an additional 163,613 shares during the period. Hedge funds and other institutional investors own 99.80% of the company’s stock.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

See Also: Systematic Risk and Investors

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.